Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Claritin-D

This article was originally published in The Tan Sheet

Executive Summary

Impax Labs granted tentative approval for generic loratadine/pseudoephedrine extended-release tablets (Schering-Plough's Claritin-D 12- and 24-Hour) on May 29 and May 24, respectively. Hayward, Calif.-based company believes it was first to file for generic 12-hour formulation. Impax, a defendant in Schering's ongoing loratadine patent litigation, also has a pending ANDA for Claritin Reditabs. In December, Impax entered into an agreement granting Novartis Consumer Health exclusive rights to market an OTC generic version of Claritin to be supplied by Impax, which is in discussions with potential OTC partners for two additional generic loratadine formulations. Novartis' Geneva Pharmaceuticals is believed to be first to file for the loratadine 10 mg tablet dosage form...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel